We are live on ! Find out more
VRAX icon

Virax Biolabs
VRAX

4 hedge funds and large institutions have $22.8K invested in Virax Biolabs in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

12.44% less ownership

Funds ownership: 12.81% → 0.37% (-12%)

20% less funds holding

Funds holding: 5 → 4 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

98% less capital invested

Capital invested by funds: $1.14M → $22.8K (-$1.12M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$10.8K
2
Millennium Management
Millennium Management
New York
+$5.5K
3
Wells Fargo
Wells Fargo
California
+$880

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.04M
2
Legal & General Group
Legal & General Group
United Kingdom
-$68.4K
3
HF
HRT Financial
New York
-$10K
4
TSS
Two Sigma Securities
New York
-$2.86K
5
UBS Group
UBS Group
Switzerland
-$2.13K

VRAX Hedge Fund Activity: Q2 2023 in Review

4 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2023, worth a combined $22.8K — down 98% from $1.14M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of VRAX and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $10.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.04M sold.

  • 4 institutional investors held Virax Biolabs (VRAX) as of Q2 2023, down from 5 in Q1 2023.
  • Funds reported $22.8K of Virax Biolabs stock for Q2 2023, down 98% quarter-over-quarter.
  • 3 funds opened new Virax Biolabs positions in Q2 2023 and 4 closed out, a net change of -1 holder.
  • The largest Virax Biolabs buyer in Q2 2023 was Renaissance Technologies, an estimated $10.8K added.
  • The largest Virax Biolabs seller in Q2 2023 was Armistice Capital, an estimated $1.04M sold.

Based on aggregated 13F filings for Q2 2023.